Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 | Werewolf Therapeutics | BUY $4 | ― | -13.80% | Reiterated | Buy Rating Affirmed for Werewolf Therapeutics Amid Strategic Advancements and Strong Financial Position | |||
 | Precigen | BUY $5 | ― | -6.20% | Reiterated | Precigen's Strategic Advancements and Pipeline Developments Drive Buy Rating | |||
| Cytokinetics | BUY $78 | ― | -6.20% | Reiterated | Cytokinetics' Promising Future: Aficamten Approval and Robust Pipeline Drive Growth Prospects | |||
| Argenx Se | BUY $696 | ― | -6.20% | Reiterated | JMP Securities Remains a Buy on Argenx Se (ARGX) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $109 | ― | 24.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $47 | ― | 19.00% | Reiterated | ||||
 | Lantheus | BUY $112 | ― | -2.70% | Reiterated | Strategic Acquisition and Pipeline Growth Fuel Lantheus Holdings' Buy Rating | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $41 | ― | 3.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $27 | ― | 2.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $115 | ― | 5.00% | Initiated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $17.5→$15.5 | ― | 1.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $28→$45 | ― | 7.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $415→$208 | ― | 23.10% | Reiterated | ||||
| Axsome Therapeutics | BUY $125 | ― | -4.20% | Reiterated | Axsome Therapeutics (AXSM) Gets a Buy from TD Cowen | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $39 | ― | 2.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $11 | ― | 10.80% | Assigned | ||||
 | EKSO BIONICS | BUY $2 | ― | -13.70% | Reiterated | Lake Street Sticks to Their Buy Rating for EKSO BIONICS (EKSO) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $40 | ― | 4.30% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $170 | ― | 8.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $237 | ― | 1.30% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $85→$95 | ― | 23.70% | Reiterated | ||||
| Nabors Industries | HOLD $77→$68 | ― | -1.60% | Reiterated | Nabors Industries price target lowered to $68 from $77 at Susquehanna | |||
| Baker Hughes Company | BUY $48→$53 | ― | -1.60% | Reiterated | Baker Hughes price target raised to $53 from $48 at Susquehanna | |||
| Valaris | HOLD $55→$50 | ― | -1.60% | Reiterated | Valaris price target lowered to $50 from $55 at Susquehanna | |||
| Helmerich & Payne | BUY $50→$47 | ― | -1.60% | Reiterated | Helmerich & Payne price target lowered to $47 from $50 at Susquehanna | |||
| TechnipFMC | BUY $37→$39 | ― | -1.60% | Reiterated | TechnipFMC price target raised to $39 from $37 at Susquehanna | |||
| Halliburton | BUY $40→$37 | ― | -1.60% | Reiterated | Halliburton price target lowered to $37 from $40 at Susquehanna | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $20 | ― | 8.80% | Reiterated | ||||
| Oil States International | HOLD $5→$5.75 | ― | -1.60% | Reiterated | Oil States price target raised to $5.75 from $5 at Susquehanna | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $2 | ― | 5.10% | Assigned | ||||
| Delta Air Lines | BUY $83 | ― | -5.80% | Reiterated | Goldman Sachs Remains a Buy on Delta Air Lines (DAL) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $16 | ― | 8.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $46 | ― | 8.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $210 | ― | 33.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $175 | ― | 6.90% | Reiterated | ||||
| Aquestive Therapeutics | BUY $9 | ― | -6.20% | Reiterated | Aquestive Therapeutics: Promising Growth Trajectory with Strategic Initiatives and Strong Market Potential | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $125→$140 | ― | 23.70% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $95→$80 | ― | 23.70% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $70→$80 | ― | 23.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $28→$25 | ― | 12.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $350 | ― | 10.30% | Initiated | ||||
| Hasbro | BUY $95 | ― | -2.50% | Reiterated | Hasbro (HAS) Receives a Buy from Bank of America Securities | |||
 | Fat Brands | BUY $15 | ― | -1.50% | Reiterated | Analysts Offer Insights on Consumer Cyclical Companies: Hermes International (Other OTC: HESAF) and Fat Brands (NASDAQ: FAT) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $15 | ― | 40.30% | Reiterated | ||||
 | Astrana Health | BUY $59→$50 | ― | -14.80% | Reiterated | Astrana Health price target lowered to $50 from $59 at Truist | |||
| Evolent Health | BUY $24→$20 | ― | -14.80% | Reiterated | Evolent Health price target lowered to $20 from $24 at Truist | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $100 | ― | 6.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $354→$352 | ― | 19.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $5 | ― | 16.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $6 | ― | 16.90% | Reiterated |
Rows:
